Harry Cassin Publisher and Editor

Andy Spalding Senior Editor

Jessica Tillipman Senior Editor

Richard L. Cassin Editor at Large

Elizabeth K. Spahn Editor Emeritus 

Cody Worthington Contributing Editor

Julie DiMauro Contributing Editor

Thomas Fox Contributing Editor

Marc Alain Bohn Contributing Editor

Bill Waite Contributing Editor

Shruti J. Shah Contributing Editor

Russell A. Stamets Contributing Editor

Richard Bistrong Contributing Editor 

Eric Carlson Contributing Editor

Bill Steinman Contributing Editor

Aarti Maharaj Contributing Editor

FCPA Blog Daily News

Entries in Johnson & Johnson (8)


Compliance Alert: Speaker fees are often toxic

Last month Forest Labs paid $38 million to settle allegations it paid doctors speaker fees for sometimes phony events so they would prescribe its drugs. It was the latest in a string of "speaker fee" cases.

Click to read more ...


Whistleblower collects $3.5 million from Johnson & Johnson unit

A former saleswoman for medical device maker Acclarent was awarded $3.5 million as her share of an $18 million settlement of a whistleblower suit alleging false marketing claims.

Click to read more ...


Alison Taylor: Does competition cause corruption?

You might expect corrupt companies to downplay and devalue the principles of market competition. In fact the opposite is true.

Click to read more ...


Robbins Geller sanctioned for relying on know-nothing ‘confidential witness’

Image courtesy of BoeingA plaintiffs law firm that specializes in securities class action litigation was ordered to pay sanctions to Boeing over a lawsuit  the firm pressed even though the crucial witness behind it didn't know anything relevant.

Click to read more ...


Issuers file conflict minerals reports, most say sourcing is unclear

Reporting companies filed Form SDs with the SEC Monday, and most said its not fully clear if their products contain conflict minerals from Africa's Congo region.

Click to read more ...


GSK will stop paying doctors for promotional speeches

GlaxoSmithKline (GSK) will not be paying doctors to promote its pharmaceutical products through speeches following a corruption scandal in China that was disclosed earlier this year. It will also not make its sales force have individual sales targets any longer.

Click to read more ...


We chat with Harvey Pitt about CCO independence, prestige

The FCPA Blog wanted to explore the idea of the dual-hatted compliance officer -- the one who occupies both the general counsel and chief compliance officer roles in a company. We talked with the former SEC Chairman and now Kalorama Partners CEO, Harvey Pitt. The conversation turned into a thoughtful exchange about what it means to be an independent and effective CCO in any industry today. Executive editor Julie DiMauro asked the questions for the FCPA Blog.

Click to read more ...


Johnson & Johnson pays $2.2 billion for U.S. kickback, off-label settlement

Health care giant Johnson & Johnson will pay more than $2.2 billion to resolve criminal and civil claims arising from allegations of kickbacks to U.S. doctors and improper marketing claims about three of its prescription drugs.

Click to read more ...